{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for ertugliflozin in Related Substance Name (approximate match)
Status:
US Approved Rx
(2017)
Source:
NDA209806
(2017)
Source URL:
First approved in 2017
Source:
NDA209806
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ertugliflozin (PF-04971729) is a potent and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. SGLT2 has become an important therapeutic target and several SGLT2-selective inhibitors are either approved or in clinical development for the management of blood glucose in patients with type 2 diabetes. Ertugliflozin demonstrated robust urinary glucose excretion in rats and an excellent preclinical safety profile. It was announced that FDA and EMA filing acceptances of three marketing applications for ertugliflozin-containing medicines for adults with type 2 diabetes.
Status:
Other
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
![Structure of 1,6-Anhydro-1-C-[4-chloro-3-[(S)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose](/img/87b20370-13a9-117b-ea1e-cb6eb655a1cb.svg?size=200&context=tmebomdeyj)
![Structure of 1,6-Anhydro-1-C-[4-chloro-3-[(R)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose](/img/dade049c-feb1-81b3-e46a-c01055a2e094.svg?size=200&context=tmebomdeyj)